- 10 hours ago
- 3 min read
A $100M market cap.A $3B opportunity.One catalyst away.
Immunic's Phase 3 oral MS drug is the only one of its kind. The market is still pricing the dilution story. We're pricing the science.
The market is confused about what happened.
In February 2026, Immunic raised $200 million in an oversubscribed private placement led by BVF Partners — one of the most sophisticated healthcare-focused investment firms in the US. The stock fell. Investors saw dilution: 229 million pre-funded warrants were issued at $0.873, tripling the fully diluted share count from ~155M to ~384M shares. H.C. Wainwright cut their price target from $8 to $5 on the share count alone — not because their view on the science changed.
Since that post-raise low, the stock has recovered to $1.115. But here is the number that matters most right now, and that most investors are not looking at carefully enough:
With that established: the raise funded Immunic through its Phase 3 readout, through a potential NDA submission, and into a 2028 approval window — without needing to raise again. The capital risk that suppressed this stock through 2025 is gone. What remains is a binary scientific bet on the most differentiated oral MS drug in Phase 3 development — at a fully diluted valuation that, in our view, does not reflect the probability-weighted upside.
The only oral MS candidate targeting neurodegeneration directly.
Vidofludimus calcium works through two pathways simultaneously. The first — DHODH inhibition — is clinically validated. It is the same target as Aubagio, one of the largest-selling oral MS drugs on the market, but more selectively and with a cleaner safety profile. The second pathway is where the differentiation lives: Nurr1 activation — a direct neuroprotective mechanism that no approved MS drug, oral or injectable, possesses.
This matters because the primary driver of long-term disability in MS is not relapse frequency. It is progressive neurodegeneration that continues even in patients whose relapses are fully controlled — what neurologists call PIRA, progression independent of relapse activity. Current oral DMTs do not address it. Vidofludimus calcium does. That is not narrative. That is a structural gap in the existing treatment landscape that a $30–45 billion market has not yet filled.
The Phase 2 data backs the mechanism. 92.3% of patients were free of confirmed disability worsening at 144 weeks in the RRMS open-label extension — a figure that competes with high-efficacy injectables. In progressive MS, the Phase 2 CALLIPER trial demonstrated statistically significant disability improvement — a rare outcome in a disease that has resisted most attempts at treating progression. The Phase 3 program — ENSURE-1 and ENSURE-2, 2,221+ patients enrolled, 15 countries — is fully recruited with a synchronized top-line readout expected by year-end 2026.
What buying here actually means.
On a fully diluted post-financing share base of approximately 384 million shares, here is how the three scenarios price out. These are R¹E estimates and should not be taken as guarantees of any outcome.
The probability-weighted expected return across all three scenarios is positive — materially so — for a position sized appropriately to the binary risk. At $1.115 per share, the current trading market cap is approximately $134M — based on ~120M basic shares, with 229M pre-funded warrants not yet reflected in that figure. On a fully diluted basis (~384M shares), the implied valuation is ~$428M. Our base case exit of $2.50–4.00 per share implies a fully diluted market cap of $960M–$1.54B. Our bull case of $5.00–8.00 implies $1.92B–$3.07B — a range consistent with where Eli Lilly and Novartis have recently valued comparable pre-approval immunology assets.
How sophisticated investors are approaching this.
A binary biotech catalyst is not a simple long. The position sizing, entry structure, and hedging approach determine whether the risk-reward is institutional-grade or speculative noise. Our full strategy brief — available to R¹E subscribers — covers the following in detail:
